Last year, NextPlat Corp generated 35.70M USD for its biggest-performing segment, Pharmacy Prescription And Other Revenue Net Of Pbm Fees. The Europe made the largest contribution, accounting for 7.45M USD last year. For the latest quarter, NextPlat Corp reported the revenue of 5.56M USD for the period ending 2026-06-30, which came from the top-performing segment, Pharmacy Prescription And Other Revenue Net Of Pbm Fees. Europe contributed the highest revenue, at 2.31M USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

Pharmacy Prescription And Other Revenue Net Of Pbm Fees

e-Commerce revenue

Pharmacy 340B contract revenue

Eliminations

FY2025

FY2024

FY2023

Pharmacy Prescription And Other Revenue Net Of Pbm Fees

35.70M(65.73%)

41.91M(63.42%)

21.41M(56.71%)

e-Commerce revenue

14.61M(26.89%)

13.79M(20.87%)

10.98M(29.07%)

Pharmacy 340B contract revenue

4.01M(7.38%)

10.38M(15.71%)

5.37M(14.21%)

Eliminations

--(--)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

Europe

North America

Asia & Pacific

Africa

South America

FY2025

FY2024

FY2023

FY2022

FY2021

Europe

7.45M(51.01%)

6.81M(49.39%)

6.69M(60.92%)

8.62M(73.59%)

5.15M(66.49%)

North America

4.68M(32.06%)

4.53M(32.84%)

2.58M(23.46%)

2.15M(18.37%)

1.78M(22.95%)

Asia & Pacific

1.97M(13.47%)

1.72M(12.47%)

1.51M(13.76%)

760.45K(6.49%)

695.77K(8.99%)

Africa

462.00K(3.16%)

683.00K(4.95%)

143.00K(1.30%)

136.05K(1.16%)

84.38K(1.09%)

South America

44.00K(0.30%)

47.00K(0.34%)

62.00K(0.56%)

45.03K(0.38%)

37.14K(0.48%)